.png)
.png)
Latest news from BIA
UK on track to beat 2016 biotech venture capital fundraising and maintain European lead in 2017
The Biotech Financing Update, January-June 2017, offers an update on the figures from the annual finance report – ‘Building something great: UK’s Global bioscience cluster’ - that the BIA produced in conjunction with their data partner Informa Pharma Intelligence. This snapshot takes a look at the headline data for the first half of 2017 and will be updated in January 2018 when the full year data will be released.
BIA responds to Prime Minister Theresa May’s Florence speech
BIA CEO, Steve Bates,responds to Prime Minister Theresa May’s Florence speech.
BIA responds to the Treasury’s Patient Capital Review
The BIA has today (Friday 22 September) welcomed the government’s proposal to establish a new National Investment Fund to support the growth of innovative UK bioscience companies.
BIA and MHRA publish report following joint conference ‘Innovation in life sciences in a changing and dynamic environment’
The UK BioIndustry Association (BIA) and the Medicines and Healthcare products Regulatory Agency (MHRA) brought together experts from across the sector to discuss some hot topics and important developments that are having an impact on the changing and dynamic UK life sciences ecosystem.
Locate Therapeutics Receives Biomedical Catalyst Primer Award To Develop Personalised Cell Therapies For Compromised Patient Populations
Locate Therapeutics' IntraStem Intracellular Delivery System offers the possibility of increasing MSC transfection rates by up to 200% Combined with the TAOS Matrix, IntraStem can deliver antibodies, magnetic nanoparticles (MNPs) and nucleic acids (plasmid (p)DNA, mRNA and siRNA) into cells at much higher levels than the current alternatives for reprogramming, as well as improving gene editing, using for example, the CRISPR-cas9 approach
Scancell appoints Dr Cliff Holloway as Chief Executive Officer
Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, is pleased to announce the appointment of Dr Cliff Holloway as Chief Executive Officer of Scancell, starting 10 January 2018. Cliff will seek to drive progress of Scancell’s immunotherapy platforms ImmunoBody® and Moditope® and oversee their commercialisation. Cliff succeeds Richard Goodfellow who will remain on the Company’s Board of Directors.
Synpromics wins best emerging UK synthetic biotech company at OBN Awards
Synpromics is thrilled to announce they have been awarded Best Emerging UK Synthetic Biotech Company at the 9th Annual OBN Awards
BTG plc acquires Roxwood Medical
London, UK, 5 October 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces it has acquired Roxwood Medical (“Roxwood”), an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease.
Guest blog: Opportunities for UK Advanced Therapies sector through Industrial Strategy Challenge Fund - competitions open as part of ISCF £146m investments
By Dr Sarah Goulding, Specialist in advanced therapies and medicines at The Knowledge Transfer Network (KTN)
CEO Update: Monday 16 October
Last Thursday we held one of the most stimulating and vibrant events of the BIA calendar – the UK Bioscience Forum. Taking place at the Queen Elizabeth II Centre in Westminster, the UKBSF brought together almost 300 people from across the sector for a jam-packed day of networking, presentations, and panel discussions.
Video of the week - Supporting innovation at Cell and Gene Therapy Catapult: an interview with Keith Thompson
In this exclusive interview, filmed at ISCT 2017, RegMedNet spoke to Keith Thompson, CEO, Cell and Gene Therapy Catapult. Keith discussed the advances that the Catapult have supported in their first 5 years, as well as what he hopes to achieve in the next 5.
A Northern Powerhouse for Life Sciences?
Every now and then, the term “Northern Powerhouse” is spotted in the headlines, and more often than not, the ensuing article is about calls for infrastructure investments. But there is exciting science across the UK, including in the North of England – so what does the Northern Powerhouse mean for the life sciences?
Influencing and shaping our sector - BIA update: April - July 2017
Ongoing BioIndustry Association (BIA) engagement enables our members’ voices to be heard at the highest levels.
Building something great: UK's Global Bioscience Cluster 2016
Growing the next generation of UK management talent
BIA directory of industry training opportunities to help build the next generation of management talent.
A vision for the UK life sciences sector in 2025
This vision, developed in consultation with the BIA Board and sector experts, sets out an ambitious goal for the UK to become a top global cluster in life sciences by 2025.